WO2001055725A3 - Diagnosis of tauopathies determining tau/phospho-tau ratio - Google Patents

Diagnosis of tauopathies determining tau/phospho-tau ratio Download PDF

Info

Publication number
WO2001055725A3
WO2001055725A3 PCT/EP2001/000560 EP0100560W WO0155725A3 WO 2001055725 A3 WO2001055725 A3 WO 2001055725A3 EP 0100560 W EP0100560 W EP 0100560W WO 0155725 A3 WO0155725 A3 WO 0155725A3
Authority
WO
WIPO (PCT)
Prior art keywords
tau
phospho
diagnosis
tauopathies
ratio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2001/000560
Other languages
French (fr)
Other versions
WO2001055725A2 (en
Inventor
Eugeen Vanmechelen
Hugo Vanderstichele
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujirebio Europe NV SA
Original Assignee
Innogenetics NV SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics NV SA filed Critical Innogenetics NV SA
Priority to DE60123752T priority Critical patent/DE60123752T2/en
Priority to JP2001555812A priority patent/JP5247963B2/en
Priority to EP01909655A priority patent/EP1250600B1/en
Priority to AU37319/01A priority patent/AU777837B2/en
Priority to CA2397991A priority patent/CA2397991C/en
Priority to HK02108310.4A priority patent/HK1048513B/en
Priority to BR0107851-8A priority patent/BR0107851A/en
Priority to DE1250600T priority patent/DE1250600T1/en
Priority to DK01909655T priority patent/DK1250600T3/en
Publication of WO2001055725A2 publication Critical patent/WO2001055725A2/en
Publication of WO2001055725A3 publication Critical patent/WO2001055725A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides a method for the diagnosis of tauopathies in an individual and/or for the differential diagnosis of a tauopathy versus a non-tauopathy based on the detection of the ratio of phospho-tau (181)/ total tau in said individual. The present invention further provides a phospho-peptide for standardization in a method of the invention.
PCT/EP2001/000560 2000-01-24 2001-01-18 Diagnosis of tauopathies determining tau/phospho-tau ratio Ceased WO2001055725A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
DE60123752T DE60123752T2 (en) 2000-01-24 2001-01-18 DIAGNOSIS OF TAUOPATHIA BY DETERMINING THE RATIO OF TAU / PHOSPHO-TAU
JP2001555812A JP5247963B2 (en) 2000-01-24 2001-01-18 Diagnosis of tauopathy
EP01909655A EP1250600B1 (en) 2000-01-24 2001-01-18 Diagnosis of tauopathies determining tau/phospho-tau ratio
AU37319/01A AU777837B2 (en) 2000-01-24 2001-01-18 Diagnosis of tauopathies determining tau/phospho-tau ratio
CA2397991A CA2397991C (en) 2000-01-24 2001-01-18 Diagnosis of tauopathies
HK02108310.4A HK1048513B (en) 2000-01-24 2001-01-18 Diagnosis of tauopathies determining tau/phospho-tau ratio
BR0107851-8A BR0107851A (en) 2000-01-24 2001-01-18 Tauopathy diagnosis
DE1250600T DE1250600T1 (en) 2000-01-24 2001-01-18 DIAGNOSIS OF TAUOPATHIA BY DETERMINING THE RATIO OF TAU / PHOSPHO-TAU
DK01909655T DK1250600T3 (en) 2000-01-24 2001-01-18 Diagnosis of tauopathies in determining the tau / phospho-tau ratio

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP00870008.0 2000-01-24
EP00870008 2000-01-24
US17839100P 2000-01-27 2000-01-27
US60/178,391 2000-01-27
EP00870280.5 2000-11-22
EP00870280 2000-11-22

Publications (2)

Publication Number Publication Date
WO2001055725A2 WO2001055725A2 (en) 2001-08-02
WO2001055725A3 true WO2001055725A3 (en) 2001-12-20

Family

ID=27223742

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/000560 Ceased WO2001055725A2 (en) 2000-01-24 2001-01-18 Diagnosis of tauopathies determining tau/phospho-tau ratio

Country Status (13)

Country Link
US (2) US6680173B2 (en)
EP (1) EP1250600B1 (en)
JP (1) JP5247963B2 (en)
AT (1) ATE342509T1 (en)
AU (1) AU777837B2 (en)
BR (1) BR0107851A (en)
CA (1) CA2397991C (en)
CY (1) CY1107993T1 (en)
DE (2) DE60123752T2 (en)
DK (1) DK1250600T3 (en)
ES (1) ES2274869T3 (en)
HK (1) HK1048513B (en)
WO (1) WO2001055725A2 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030162230A1 (en) * 2000-09-27 2003-08-28 Reagan Kevin J. Method for quantifying phosphokinase activity on proteins
JP4681175B2 (en) * 2001-09-28 2011-05-11 三菱化学メディエンス株式会社 Method for detecting disseminated intravascular coagulation syndrome and its pre-onset stage
JP4393382B2 (en) * 2002-08-14 2010-01-06 三菱化学株式会社 Central tau protein specific antibody
WO2004081534A2 (en) * 2003-03-12 2004-09-23 Assay Designs, Inc. Phosphokinase assay
CA2445420A1 (en) * 2003-07-29 2005-01-29 Invitrogen Corporation Kinase and phosphatase assays
US7619059B2 (en) * 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes
US7727752B2 (en) * 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
US7238788B2 (en) * 2004-02-18 2007-07-03 University Of Iowa Foundation Antibodies to phosphorylated tau, methods of making and methods of use
JP4730584B2 (en) 2004-12-06 2011-07-20 東亞合成株式会社 Antibacterial peptides and their use
WO2007068105A1 (en) * 2005-12-12 2007-06-21 Robarts Research Institute Method of diagnosing amyotrophic lateral sclerosis
CA2725143A1 (en) * 2008-05-21 2009-11-26 Neurotez, Inc. Methods for treating progressive cognitive disorders related to neurofibrillary tangles
CN102549438B (en) * 2009-09-24 2014-10-29 国家健康与医学研究院 FKBP52-TAU Interaction as a Novel Therapeutic Target for Neurological Disorders Involving TAU Dysregulation
WO2011109112A2 (en) * 2010-03-05 2011-09-09 Albert Einstein College Of Medicine Of Yeshiva University Method of detecting tau protein and tau fragments in serum
US20130052669A1 (en) * 2010-04-30 2013-02-28 Amanda G. Paulovich Compositions and methods for reliably detecting and/or measuring the amount of a modified target protein in a sample
US20120244174A1 (en) * 2011-01-31 2012-09-27 Intellect Neurosciences Inc. Treatment of tauopathies
WO2012142301A2 (en) 2011-04-12 2012-10-18 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury
GB201111361D0 (en) * 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
NZ630542A (en) * 2012-08-16 2017-06-30 Ipierian Inc Methods of treating a tauopathy
WO2014039630A2 (en) * 2012-09-05 2014-03-13 Emory University Diagnostic testing in dementia and methods related thereto
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
BR112015030356A2 (en) 2013-06-10 2017-12-05 Ipierian Inc methods of treatment of a taupathy
AU2014368696A1 (en) 2013-12-20 2016-06-02 F. Hoffmann-La Roche Ag Humanized anti-Tau(pS422) antibodies and methods of use
JP2017512751A (en) 2014-02-14 2017-05-25 アイピエリアン，インコーポレイティド Tau peptides, anti-tau antibodies, and methods for their use
CN106605146B (en) * 2014-04-08 2020-07-28 佛罗里达大学研究基金会有限公司 Protein markers for acute, subacute and chronic traumatic injury of the central nervous system
AR100978A1 (en) 2014-06-26 2016-11-16 Hoffmann La Roche ANTI-Tau HUMANIZED ANTIBODY BRAIN LAUNCHERS (pS422) AND USES OF THE SAME
DE102014013571A1 (en) * 2014-09-18 2016-03-24 Aj Roboscreen Gmbh Monoclonal antibody to human TAU protein
US20180050097A1 (en) * 2015-03-25 2018-02-22 Stc. Unm Immunotherapy compositions and methods for treatment of tauopathy and transgenic mouse
WO2016207245A1 (en) 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Humanized anti-tau(ps422) antibodies and methods of use
KR102033776B1 (en) * 2017-10-31 2019-10-17 가천대학교 산학협력단 Diagnostic composition of alzheimer's disease severity comprising agents measuring expression level of tau protein and diagnostics method of alzheimer's disease severity using the same
CA3093200A1 (en) * 2018-03-05 2019-09-12 Janssen Pharmaceutica Nv Anti-phf-tau antibodies and uses thereof
WO2020105700A1 (en) * 2018-11-22 2020-05-28 富士レビオ株式会社 Antibody conjugate
CN113748343A (en) * 2019-03-28 2021-12-03 H.隆德贝克有限公司 Use of the pS396 assay for diagnosing TAU proteinopathies
WO2020201828A1 (en) 2019-04-05 2020-10-08 Tauc3 Biologics Limited Anti-tauc3 antibodies and uses thereof
KR102905634B1 (en) * 2019-05-31 2025-12-30 일라이 릴리 앤드 캄파니 Compounds and methods targeting human tau
CN115066610A (en) * 2020-02-05 2022-09-16 住友制药株式会社 Reagent and method for determining TAU pathological changes and dementia-related diseases
KR20240134175A (en) * 2022-01-12 2024-09-06 지틴벤트 리미티드 Method for detecting tau protein fragments in a sample

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003369A1 (en) * 1991-08-01 1993-02-18 Voorheis Paul H Diagnostic method for alzheimer's disease
WO1994013795A1 (en) * 1992-12-14 1994-06-23 N.V. Innogenetics S.A. Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications
WO1994018560A1 (en) * 1993-02-12 1994-08-18 Teijin Limited Method of assaying human tau protein, kit therefor, and diagnostic method
WO1995017429A1 (en) * 1993-12-21 1995-06-29 Innogenetics N.V. Monoclonal antibodies specific for phf-tau, hybridomas secreting them, antigen recognition by these antibodies and their applications
WO1996004309A1 (en) * 1994-07-29 1996-02-15 Innogenetics N.V. Monoclonal antibodies specific for an epitope of a particular subclass or form of phosphorylated tau, hybridomas secreting them, antigen recognition of these antibodies and their applications
WO1997034145A1 (en) * 1996-03-13 1997-09-18 Mitsubishi Chemical Corporation Antiphosphorylated tau protein antibody and method for detecting alzheimer's disease with the use of the same
WO1999062548A1 (en) * 1998-06-01 1999-12-09 Advanced Research And Technology Institute Methods and compositions for diagnosing tauopathies

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003369A1 (en) * 1991-08-01 1993-02-18 Voorheis Paul H Diagnostic method for alzheimer's disease
WO1994013795A1 (en) * 1992-12-14 1994-06-23 N.V. Innogenetics S.A. Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications
WO1994018560A1 (en) * 1993-02-12 1994-08-18 Teijin Limited Method of assaying human tau protein, kit therefor, and diagnostic method
WO1995017429A1 (en) * 1993-12-21 1995-06-29 Innogenetics N.V. Monoclonal antibodies specific for phf-tau, hybridomas secreting them, antigen recognition by these antibodies and their applications
WO1996004309A1 (en) * 1994-07-29 1996-02-15 Innogenetics N.V. Monoclonal antibodies specific for an epitope of a particular subclass or form of phosphorylated tau, hybridomas secreting them, antigen recognition of these antibodies and their applications
WO1997034145A1 (en) * 1996-03-13 1997-09-18 Mitsubishi Chemical Corporation Antiphosphorylated tau protein antibody and method for detecting alzheimer's disease with the use of the same
WO1999062548A1 (en) * 1998-06-01 1999-12-09 Advanced Research And Technology Institute Methods and compositions for diagnosing tauopathies

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BLENNOW K ET AL: "Tau protein in cerebrospinal fluid: A biochemical marker for axonal degeneration in Alzheimer disease?", MOLECULAR AND CHEMICAL NEUROPATHOLOGY, vol. 26, no. 3, December 1995 (1995-12-01), pages 231 - 245, XP001006261, ISSN: 1044-7393 *
HESSE CAMILLA ET AL: "Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke.", NEUROSCIENCE LETTERS, vol. 297, no. 3, 19 January 2001 (2001-01-19), pages 187 - 190, XP001004722, ISSN: 0304-3940 *
OTTO MARKUS ET AL: "Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease.", NEUROSCIENCE LETTERS, vol. 225, no. 3, 1997, pages 210 - 212, XP001003009, ISSN: 0304-3940 *
VANMECHELEN E ET AL: "Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: A sandwich ELISA with a synthetic phosphopeptide for standardization.", NEUROSCIENCE LETTERS, vol. 285, no. 1, 5 May 2000 (2000-05-05), pages 49 - 52, XP000972339, ISSN: 0304-3940 *

Also Published As

Publication number Publication date
CA2397991A1 (en) 2001-08-02
DK1250600T3 (en) 2007-02-05
DE60123752D1 (en) 2006-11-23
DE1250600T1 (en) 2003-03-06
CY1107993T1 (en) 2013-09-04
ES2274869T3 (en) 2007-06-01
AU777837B2 (en) 2004-11-04
BR0107851A (en) 2002-10-29
EP1250600B1 (en) 2006-10-11
HK1048513B (en) 2007-12-07
DE60123752T2 (en) 2007-08-23
US6680173B2 (en) 2004-01-20
AU3731901A (en) 2001-08-07
US7387879B2 (en) 2008-06-17
US20030194742A1 (en) 2003-10-16
CA2397991C (en) 2017-10-24
ATE342509T1 (en) 2006-11-15
HK1048513A1 (en) 2003-04-04
WO2001055725A2 (en) 2001-08-02
JP5247963B2 (en) 2013-07-24
US20040091942A1 (en) 2004-05-13
JP2003521499A (en) 2003-07-15
EP1250600A2 (en) 2002-10-23

Similar Documents

Publication Publication Date Title
WO2001055725A3 (en) Diagnosis of tauopathies determining tau/phospho-tau ratio
WO2002055128A3 (en) Fluid delivery and measurement systems and methods
WO2005020790A3 (en) Automated methods and systems for vascular plaque detection and analysis
MXPA01010640A (en) Measurement and use of molecular interactions.
WO2002027326A3 (en) Method and kit for the transderaml determination of analyte concentration in blood
MXPA03003682A (en) Method of determining global coagulability and hemostatic potential.
ITTO20010411A0 (en) METHOD AND DEVICE FOR PERFORMING HIGH PROCESSIVE AND HIGH BIOLOGICAL VALUE TEST AND ASSAY ON CELLS AND/OR COMPOUNDS.
WO2000002053A3 (en) Differential diagnosis of neurodegeneration
WO2002010747A3 (en) Method and apparatus for patch-clamp measurements on cells
WO2001032876A3 (en) Compositions and methods for determining interactions of mitochondrial components, and for identifying agents that alter such interactions
WO2002046746A3 (en) Method for detection of vitamin d metabolites
WO2003045310A8 (en) Digital assay
AU4322999A (en) Methods and compositions for diagnosing tauopathies
CA2315186A1 (en) Methods for the recovery and measurement of troponin complexes
WO2002008461A3 (en) A METHOD AND AN ALGORITHM FOR mRNA EXPRESSION ANALYSIS
WO2002079754A3 (en) Contact potential difference sensor to monitor oil properties
WO2004094675A3 (en) Compositions and methods for determining the presence of sars coronavirus in a sample
WO2003050291A3 (en) Sensor for the use in testing biological chemical or environmental samples
WO2001055719A3 (en) Diagnostic kit for detecting creatine levels
AU2001249444A1 (en) Methods and compositions for the simultaneous detection of multiple analytes
WO1999050171A3 (en) Fluid sampling tool
WO2003084384A3 (en) Diagnosis of flavivirus infection
WO2004070333A3 (en) Method for determining at least one state parameter of a sealing system and sealing system
WO2002059600A3 (en) Analyte detection
WO2002100805A3 (en) Colorimetric nanocrystal sensors, methods of making, and use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

EL Fr: translation of claims filed
WWE Wipo information: entry into national phase

Ref document number: 2001909655

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2397991

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 37319/01

Country of ref document: AU

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 555812

Kind code of ref document: A

Format of ref document f/p: F

TCAT At: translation of claims filed
WWP Wipo information: published in national office

Ref document number: 2001909655

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 37319/01

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 2001909655

Country of ref document: EP